Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some core label elements are matched (e.g., Pentasa brand/mesalazine, UC adult indication, renal evaluation, contraindication, some hypersensitivity/symptom monitoring concepts). However, several common-use/general statements are not supported by the provided label text (e.g., Crohn’s disease use, “commonly prescribed”), and key dosing/administration and counseling details are not fully aligned (e.g., induction vs maintenance, dosing frequency tied to label, pediatric/pregnancy claims).
Category Scores
Accurate Statements
Pentasa 1g is a brand of mesalazine (5-aminosalicylic acid, 5-ASA).
Label text provided does not explicitly state “Pentasa is mesalazine/5-ASA”; however, multiple label sections refer to PENTASA products that contain mesalamine or are converted to mesalamine and discuss mesalamine mechanisms/warnings, which supports that Pentasa contains mesalamine.
Mesalazine is used to treat inflammatory bowel disease.
Indication section specifies treatment of ulcerative colitis (an IBD), but label text provided does not explicitly say “inflammatory bowel disease” phrase.
Pentasa is used to help maintain remission in inflammatory bowel disease.
Indications include induction of remission (label wording: “induction of remission”). The claim uses “maintain remission,” which is not explicitly stated in provided indications, but is directionally related to remission.
Serious but uncommon reactions to Pentasa (mesalazine) can include kidney problems.
Warnings and Precautions 5.1: renal impairment (including renal failure) reported.
Serious but uncommon reactions to Pentasa (mesalazine) can include severe hypersensitivity.
Warnings and Precautions 5.3: hypersensitivity reactions and internal organ involvement; severe cutaneous adverse reactions also linked to hypersensitivity.
Urgent medical advice is recommended for symptoms such as reduced urination, rash or swelling, or breathing trouble.
Label supports urgent evaluation for hypersensitivity signs/symptoms (5.3) and discontinuation/consider further evaluation for severe cutaneous adverse reactions (5.5), but it does not list “reduced urination,” “swelling,” or “breathing trouble” explicitly in the provided excerpts.
Mesalazine has alternatives in many brands and formulations.
Mesalazine is taken regularly as directed to help prevent flare-ups.
Clinical studies describe a regimen of 1 g four times daily; however “flare-ups”/prevention is not explicitly phrased in the provided label.
Unsupported Statements
Pentasa 1g is a brand of mesalazine (5-aminosalicylic acid, 5-ASA).
Provided label text does not explicitly connect “5-ASA/5-aminosalicylic acid” to mesalamine in the excerpts.
Pentasa is commonly prescribed for ulcerative colitis.
No “commonly prescribed” or utilization language appears in the provided label excerpts.
Pentasa is commonly prescribed for Crohn’s disease.
The provided indication section is only for ulcerative colitis in adults; no Crohn’s disease indication is provided in the excerpts.
“1g” on Pentasa prescriptions refers to the dose strength per tablet or sachet.
The provided label excerpt lists a regimen dose of 1 g (4 x 250 mg capsules or 2 x 500 mg capsules) administered orally four times daily, but does not define what “1g” means on prescriptions as “dose strength per tablet or sachet.”
The “1g” dose strength is commonly 1,000 mg of mesalazine per unit.
The label supports 1 g oral dose regimen, but does not state that 1 g is “commonly” 1,000 mg mesalazine per unit.
The dose strength is selected based on the severity of symptoms and the dosing schedule prescribed by a clinician.
The provided label excerpt gives a recommended dosage regimen and does not describe individualized dose selection based on severity.
Mesalazine is taken regularly as directed to control inflammation.
Label describes topical anti-inflammatory mechanism and clinical outcomes, but does not provide patient-counseling language equivalent to “taken regularly...to control inflammation.”
Pentasa (mesalazine) may cause gastrointestinal symptoms such as nausea.
No specific adverse reaction list (e.g., nausea) is provided in the excerpted label.
Pentasa (mesalazine) may cause gastrointestinal symptoms such as abdominal discomfort.
The mesalamine-induced acute intolerance syndrome includes acute abdominal pain, but “abdominal discomfort” and GI symptom broadness are not explicitly stated.
Pentasa (mesalazine) may cause gastrointestinal symptoms such as diarrhea.
Acute intolerance syndrome includes bloody diarrhea; the claim is broader (“diarrhea”) and not explicitly tied to Pentasa overall adverse reactions in provided excerpt.
Pentasa (mesalazine) may cause headache.
Acute intolerance syndrome lists sometimes headache, but the claim is generalized as a possible side effect; not presented as general adverse reaction in provided excerpt.
Pentasa (mesalazine) may cause allergic or intolerance reactions.
Hypersensitivity reactions and acute intolerance syndrome are described, but the claim is overly general and not directly stated in those exact terms in the excerpt.
Use of mesalazine in children and during pregnancy depends on the specific IBD, disease severity, and clinician judgement.
The provided label excerpt includes pregnancy section header but does not provide pregnancy content; pediatric use states safety/effectiveness have not been established. The claim’s specific determinants are not supported by provided excerpts.
Mesalazine is one of the older IBD medicines used in pregnancy and in children.
No such statements are present in the provided label excerpts.
The decision to use mesalazine in pregnancy is individualized.
Pregnancy content is not provided in the excerpts; no individualized decision language is supported.
Mesalazine alternatives include different release profiles.
The provided label excerpt shows extended-release capsules only for Pentasa dosing forms, but does not state that mesalazine alternatives “include different release profiles.”
Alternatives are often chosen based on how the disease responds.
No label support in provided excerpts.
Alternatives are often chosen based on whether prolonged or targeted release is needed.
No label support in provided excerpts.
Alternatives are often chosen based on dosing convenience and insurance or availability.
No label support in provided excerpts.
Contradictions
High
AI Statement
Pentasa is commonly prescribed for Crohn’s disease.
Label Reference
1 INDICATIONS AND USAGE: “induction of remission and for the treatment of mildly to moderately active ulcerative colitis in adult patients.”
Important Omissions
The label’s recommended dosage regimen for adults with mildly to moderately active ulcerative colitis: 1 g orally four times daily (specified as 4 x 250 mg or 2 x 500 mg capsules).
Importance:
Moderate
Renal function evaluation prior to initiation and periodically while on therapy, and discontinuation if renal function deteriorates (monitoring instruction).
Importance:
Moderate
Important administration instructions: swallow capsules whole; do not crush/chew; or open capsule and sprinkle contents onto applesauce/yogurt and consume immediately; drink adequate fluids.
Importance:
Moderate
Pediatric use statement: safety/effectiveness not established.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
A high-importance contradiction exists (Crohn’s disease use claim unsupported by the provided label). Additionally, pregnancy/children claims are not supported by provided excerpts, and monitoring/administration specifics are largely omitted, which could affect safe and accurate use.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Crohn’s disease use claim conflicts with provided indication (ulcerative colitis in adults). Several other statements (common prescribing, dosage-strength interpretation, pediatric/pregnancy determinants, and specific adverse reactions like nausea) are not supported by the provided label excerpts.
Suggested Improvement
Restrict indications to adult ulcerative colitis as stated; remove Crohn’s disease language. Quote or closely mirror label-supported dosing (1 g four times daily) and administration instructions. Replace generalized adverse-event possibilities with those explicitly described in the label excerpts (e.g., acute intolerance syndrome symptoms; hypersensitivity/internal organ involvement). For pediatric/pregnancy, only use statements supported by the provided label text (pediatric safety/effectiveness not established; pregnancy content not provided).